Sodium Adenosine Triphosphate (ATP) is a critical metabolic preparation designed to provide direct energetic support to cellular processes. As the primary energy currency of the cell, this pharmacological form of ATP is used to compensate for energy deficiencies in tissues suffering from ischemia, hypoxia, or degenerative changes. It plays a vital role in regulating metabolic processes in the myocardium, skeletal muscles, and nervous system, making it an essential tool in treating cardiovascular disorders and neuromuscular diseases where cellular energy production is compromised.
Each 1ml ampoule contains:
Active Ingredient: Sodium Adenosine Triphosphate (calculated as the anhydrous substance) — 10 mg.
Excipients: Water for injection and pH stabilizers.
The active substance is a sodium salt of the adenosine triphosphate ester, which is chemically identical to the endogenous ATP produced within the mitochondria of human cells.
Sodium Adenosine Triphosphate exerts a powerful hypotensive, antiarrhythmic, and metabolic effect. Its mechanism of action involves several pathways:
Energy Metabolism: Once administered, it breaks down into adenosine and inorganic phosphate, releasing energy that supports the sodium-potassium pump and maintains cellular ionic balance.
Vasodilation: It interacts with purinergic receptors (P1 and P2) on the vascular smooth muscle, leading to coronary and peripheral vasodilation, which improves oxygen delivery to the tissues.
Membrane Stabilization: It stabilizes cell membranes and prevents the loss of potassium ions, which is crucial for myocardial stability.
Antiarrhythmic Effect: It slows down the conduction of electrical impulses through the atrioventricular (AV) node, making it effective in terminating certain types of supraventricular tachycardias.
This medication is prescribed for a wide range of conditions involving metabolic dysfunction:
Muscular Dystrophy: Progressive forms of muscle atrophy and weakness.
Cardiovascular Disorders: Complex therapy for myocardial dystrophy, post-infarction cardiosclerosis, and coronary artery disease.
Arrhythmias: Management of paroxysmal supraventricular tachycardia.
Neurological Conditions: Auxiliary treatment for poliomyelitis and peripheral nerve injuries.
Vascular Health: Treatment of Raynaud's disease and obliterating thromboangiitis.
Ophthalmology: Sometimes used in the management of hereditary retinal degeneration.
The use of Sodium Adenosine Triphosphate is contraindicated in the following cases:
Acute Myocardial Infarction: During the very early stages of an unstable heart attack.
Hyperkalemia and Hypermagnesemia: Excessively high levels of potassium or magnesium in the blood.
Severe Bronchial Asthma: Due to the risk of bronchospasm triggered by adenosine.
AV Block: Second or third-degree atrioventricular block (without a pacemaker).
Hypersensitivity: Known allergy to any component of the formulation.
Hemorrhagic Stroke: Active bleeding in the brain.
The solution is typically administered intramuscularly or intravenously (slowly or by bolus depending on the indication).
For Metabolic Support: Usually 1 ml (10 mg) injected intramuscularly 1–2 times daily for 10–14 days.
For Arrhythmia Termination: Administered intravenously as a rapid bolus (within 2–5 seconds) under strict medical supervision and ECG monitoring.
Bolus Speed: For antiarrhythmic effects, the speed of IV injection is critical; slow administration may result in the drug being metabolized before reaching the heart.
Site Rotation: When using intramuscularly, rotate injection sites to prevent local irritation.
Medical Supervision: Intravenous administration should only be performed in a clinical setting.
Cardiovascular System: Flushing of the face, bradycardia (slow heart rate), chest pain, or transient hypotension.
Respiratory System: Shortness of breath or bronchospasm (rare).
Gastrointestinal System: Nausea, epigastric discomfort, or increased intestinal motility.
Allergic Reactions: Skin rash, itching, or urticaria.
Neurological: Headache, dizziness, or a feeling of faintness.
Pregnancy and Lactation: Safety has not been fully established; use only if the potential benefit outweighs the risk to the fetus or infant.
Driving: Patients should observe their reaction to the drug before operating heavy machinery, as dizziness may occur.
Drug Interactions: Do not use concurrently with high doses of caffeine or theophylline, as they antagonize the effects of ATP. It may enhance the action of magnesium and calcium channel blockers.
Elderly Patients: Monitor heart rhythm closely due to increased sensitivity to conduction changes.
Store in the original packaging to protect from light at a temperature between 2°C and 8°C (refrigerated). Do not freeze. Keep out of reach of children. The shelf life is typically 2 years; do not use after the expiration date printed on the ampoule.
There are no reviews for this product.